Haplogen is a privately held biotechnology company based on an entirely novel genetics technology platform. Its goal is to combat infectious diseases. Our mission is to discover and develop therapeutics to treat infectious diseases. Haplogen's most advanced program has developed protective compounds against respiratory Virus infection and has entered preclinical development.
R&D:Haplogen discovers and develops novel antiviral therapeutic agents. Haplogen's most advanced therapeutic program develops therapeutic compounds to prevent exacerbations for patients with obstructive lung diseases (asthma, COPD and others) that are caused by infections with the common cold virus.
Sales/Distribution:Haplogen partners with pharma and biotechnology companies to develop medication against COPD and asthma exacerbations. Contact: office@haplogen.com
Campus Vienna Biocenter 3
1030 Vienna
Vienna
Contact: Georg Casari (CEO)
Telephone: +43 (1) 9165522
Email: office@haplogen.com
Website